Billion-Dollar Hunter Deerfield Bets Big on AI Drugmaker with $1.6B TCE Deal

Amino Observation - Original Production by the AI Drug Discovery Group

Author | Cai Jiu

/ 01 /

The New Target of the Billion-Dollar Hunter

Deerfield’s goal is undoubtedly to continuously replicate the next Nuvalent.

Reviewing Nuvalent’s Path to Success: Deerfield’s Ability to Achieve a Multi-Billion-Dollar M&A Exit Stems from a Complete, Replicable Incubation Closed-Loop Strategy.

Step 1: Secure the source of exclusive proprietary technology. The institution’s industry team partnered with Professor Matthew Shair of Harvard University to anchor a differentiated small-molecule kinase technology characterized by high selectivity, capable of overcoming tumor drug resistance and penetrating the blood-brain barrier. The two parties jointly established Nuvalent.

Step 2: Covering all early-stage funding. As the sole founding investor, Deerfield fully funded the seed round, covering all R&D and facility expenses during the company’s startup phase, thereby eliminating the need for external equity dilution through fundraising.

Step 3: Complete the Mature Industry Management Team. Deerfield will introduce senior executives from established pharmaceutical companies and a full suite of clinical operations management, while the R&D team focuses on tackling key technical challenges, ensuring a continuous pipeline of industry talent to drive operations.

Throughout the entire process, deep empowerment was central. We were deeply involved in defining the clinical positioning of the pipeline, building a global clinical development network and establishing access to capital markets. Once the pipeline matured, we led the engagement with multinational pharmaceutical companies, ultimately facilitating GSK’s all-cash acquisition worth tens of billions of US dollars, thereby completing the full exit cycle.

The strategic partnership with Heji Tai Technology marks another implementation of this incubation paradigm.

Boulevard Bio, which has acquired the global rights to TCE3, a tri-specific T-cell engager, is a privately held biotech company wholly owned and internally incubated by Deerfield. Its incubation structure and operational model are directly inherited from Nuvalent. It is not difficult to surmise that Boulevard Bio is highly likely to be Deerfield’s next-generation incubation platform, in which it places significant hopes following the completion of the Nuvalent acquisition.

The recent landmark overseas licensing deal for TCE marks Boulevard Bio’s first major pipeline transaction. A new round of the “cultivation” game has begun.

Deerfield’s Bet on the TCE Sector Is Easy to Understand. From a Mid-to-Long-Term Industry Perspective, T-Cell Engagers Will Be the Core Flagship Assets of Innovative Drugs in the Next Decade.

TCEs are essentially bispecific or multispecific antibodies that act as “molecular bridges” in vivo: one end binds to the target antigen, while the other anchors to T cells, bringing the two cell types into close proximity to form an immune synapse. This activates endogenous T cells to kill diseased cells, a mechanism of action applicable to both the oncology and autoimmune disease sectors.

More critically, the value of this therapeutic赛道 is being continuously validated by clinical data. Multiple TCEs in the field of hematologic malignancies have already achieved commercialization, demonstrating the maturity of the therapy; Amgen’s Tarlatamab became the first approved TCE for solid tumors globally, breaking through treatment bottlenecks for solid tumors and thoroughly igniting investment enthusiasm in the industry; meanwhile, autoimmune pipelines continue to yield positive clinical signals, further expanding the long-term growth potential of this sector.

The robust clinical prospects have directly fueled transactional activity in the industry. Nearly all leading multinational pharmaceutical companies have established their proprietary TCE technology platforms through in-house R&D or pipeline in-licensing. Among them, AbbVie has adopted the most aggressive strategy, making multiple acquisitions and entering into collaborations to build its pipeline, with cumulative investments approaching $5 billion. This underscores the long-term strategic importance that MNCs attach to this therapeutic area.

Amid intensifying competition within the sector, differentiated competition at the molecular and platform levels is the key to success, and MTS-128 has established three clear layers of competitive barriers.

First, molecular design possesses inherent advantages.Leveraging the NanoForge comprehensive AI system for the targeted generation of nanobody units, the platform utilizes molecular dynamics pre-simulation of three-dimensional spatial conformations to proactively mitigate common challenges associated with multi-target TCEs, such as steric hindrance and insufficient efficiency in simultaneous dual-target binding. Meanwhile, the adoption of a miniaturized structure enhances lesion tissue penetration, while the incorporation of an HSA-binding domain extends in vivo half-life, thereby comprehensively optimizing pharmacokinetic performance.

Second, the mechanism of action achieves intergenerational upgrading.Compared with traditional bispecific T-cell engagers (TCEs), trispecific TCEs can simultaneously modulate a broader range of biological mechanisms, potentially enhancing target cell cytotoxicity while balancing the intensity of immune activation to widen the safety window, improve therapeutic selectivity, and enhance safety profiles, thereby enabling simultaneous coverage of multiple indication areas in both hematologic malignancies and autoimmune diseases.

Third, the R&D model significantly improves clinical success rates.The entire molecule was designed, screened, and optimized using the NanoForge end-to-end AI molecular engineering platform. By leveraging protein prediction models for batch screening of high-quality sequences, this approach eliminates the inefficiencies of traditional antibody high-throughput wet-lab trial-and-error methods, thereby offering a higher potential success rate.

It is precisely this layered, progressively differentiated technological moat that enabled MTS-128 to secure a globally exclusive licensing deal—setting a new record in China—during the preclinical stage, thereby naturally becoming the first core pipeline asset for Boulevard Bio, Deerfield’s newly launched internal incubation platform.

However, the real highlight of the collaboration between Deerfield and Jitai Technology extends far beyond the single MTS-128 pipeline launched this time.

According to the previously stated position, the agreement reached by both parties is not a one-off project transaction, but a long-term strategic alliance with deep binding.The essence of the partnership lies in Jitai Technology’s continuous delivery of platform-based pipeline output, complemented by Deerfield’s global clinical resources, industry network, and capital operation capabilities, thereby mutually amplifying and compounding the value for both parties.This means that both parties may continue to execute more licensing deals similar to MTS-128 in the future, creating more potential blockbusters worth tens of billions of dollars.

The rationale is straightforward. Jitai’s core positioning is that of a platform-based AI pharmaceutical company strategically positioned for the era of macromolecular innovation. Its proprietary NanoForge system has established four modular AI R&D matrices: AiLNP, responsible for nucleic acid delivery design; AiRNA, for optimizing mRNA sequence efficiency; AiTEM, empowering small-molecule formulation development; and AiProtein, focused on de novo protein and antibody design.The four major modules establish a full-chain closed loop spanning from AI-driven molecular design and nanodelivery system engineering to the development of novel therapies, covering the most advanced technological frontiers in current innovative drug development.

This strategic layout precisely aligns with the structural inflection point in global innovative drug development. The industry is bidding farewell to the era dominated solely by small-molecule drugs and has officially entered a new stage characterized by parallel advancements and breakthroughs across multiple technologies, including large-molecule antibodies, mRNA, siRNA, gene editing, and cell therapy. Diversified novel modalities have become the central theme of innovation for the next decade. Compared to traditional small molecules, large-molecule drugs offer significant advantages in target specificity, therapeutic potential, and scope for indication expansion, making them the core focus of continued investment by multinational pharmaceutical companies and top-tier healthcare capital.

More importantly, NanoForge is not merely a conceptual platform confined to paper and the laboratory, but a robust R&D infrastructure that has already undergone industrialization validation.The platform boasts a patent portfolio of tens of millions of lipids, multiple clinical pipelines in development, and several executed commercial business development (BD) deals, thereby validating its technological capabilities, data accumulation, and commercial value.

In the TCE field alone, MediciNova has a robust pipeline. For instance, MTS-105 has received orphan drug designation from the U.S. FDA based on its strong preclinical data and is currently in the IIT study phase.

This is also the core prerequisite that enabled both parties to swiftly finalize their strategic cooperation and implement a benchmark TCE outbound transaction within a short period.

For both parties, this strategic collaboration represents a classic case of mutual commitment, with the potential for value resonance possibly exceeding expectations.After all, Deerfield incubated Nuvalent, guiding it from a startup team to a billion-dollar M&A exit in less than ten years, fully validating its mature model of “source incubation + full-cycle empowerment + MNC acquisition exit.”

Of course, for Jitai itself, the gains extend beyond the potential high returns from its collaboration with Deerfield.The NanoForge platform serves as the foundation of its core growth flywheel. The company simultaneously pursues a dual strategy of “in-house pipeline development + global ecosystem collaborations.” Each advancement in the pipeline and every overseas licensing deal generates vast amounts of experimental data and molecular optimization insights, which continuously feed back to iteratively refine AI models. This enhances capabilities in molecular design, screening, and optimization, thereby consistently yielding highly differentiated, high-success-rate, and commercially valuable drug candidates, creating a self-reinforcing positive cycle.

This logic, driven by platforms and characterized by sustainable, accelerating viral growth, is a typical microcosm of AI drug discovery transitioning from a technological concept to industrial implementation. The convergence of industry trends with companies’ continuous technical accumulation through deep cultivation has made the systematic revaluation of the AI drug discovery sector an unstoppable momentum.